Schuler AD1, Engles CA2, Maeda DY2, Quinn MT3, Kirpotina LN3, Wicomb WN4, Mason SN5, Auten RL5, Zebala JA2.
Bioorg Med Chem Lett. 2015 Sep 15;25(18):3793-7. doi: 10.1016/j.bmcl.2015.07.090. Epub 2015 Jul 30.The chemokine receptors CXCR1 and CXCR2 are important pharmaceutical targets due to their key roles in inflammatory diseases and cancer progression. We have previously identified 2-[5-(4-fluoro-phenylcarbamoyl)-pyridin-2-ylsulfanylmethyl]-phenylboronic acid (SX-517) and 6-(2-boronic acid-5-trifluoromethoxy-benzylsulfanyl)-N-(4-fluoro-phenyl)-nicotinamide (SX-576) as potent non-competitive boronic acid-containing CXCR1/2 antagonists. Read More